Trial site
Hyōgo
Hyōgo, 673-8558, JapanNot linked to an institution yet
- 15running trials
- 5closed trials
The trials here
What the 20 trials at this site are about, from their registry records.
- Phase
- Phase 313 trials
- Phase 26 trials
- Phase 41 trial
- Status
- Active, not recruiting8 trials
- Recruiting7 trials
- Completed4 trials
- Withdrawn1 trial
Running trials
Recruiting
A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
NCT07684612· Phase 3· GlaxoSmithKline· Source
Contact: Kasumi Yamamoto (principal investigator)
Recruiting
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
NCT07286266· Phase 3· GlaxoSmithKline· Source
Contact: Kasumi Yamamoto (principal investigator)
Recruiting
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
NCT07286331· Phase 3· GlaxoSmithKline· Source
Contact: Kasumi Yamamoto (principal investigator)
Recruiting
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051· Phase 2· GlaxoSmithKline· Source
Contact: Ryo Tachikawa (principal investigator)
Recruiting
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation
NCT06959095· Phase 3· GlaxoSmithKline· Source
Contact: Ryo Tachikawa (principal investigator)
Active, not recruiting
A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma
NCT06748053· Phase 2· GlaxoSmithKline· Source
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101· Phase 3· GlaxoSmithKline· Source
Contact: Mitsumasa Watanabe (principal investigator)
Active, not recruiting
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
NCT06537414· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
NCT06472076· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer
NCT06317311· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
Pragmatic Open - Label Randomized Clinical Trial of FF/UMEC/VI vs Non-ellipta Usual Care ICS-LABA for Adult Participants With Uncontrolled Asthma
NCT06372496· Phase 4· GlaxoSmithKline· Source
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588· Phase 3· GlaxoSmithKline· Source
Contact: Naomi Kiyota (principal investigator)
Active, not recruiting
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
NCT06062420· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer
NCT05565378· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT04246047· Phase 3· GlaxoSmithKline· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error